

RECEIVED

APR 25 2003

TECH CENTER 1600



1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/661,992B

DATE: 04/21/2003

TIME: 15:32:39

Input Set : A:\-59.app

Output Set: N:\CRF4\04212003\I661992B.raw

```

3 <110> APPLICANT: Scheifflinger, Friedrich
4     Kerschbaumer, Randolph
5     Falkner, Falko-Guenter
6     Dorner, Friedrich
7     Baxter Aktiengesellschaft
9 <120> TITLE OF INVENTION: Factor IX/Factor IXa Activating Antibodies and Antibody
10    Derivatives
12 <130> FILE REFERENCE: 20695C-005900US
14 <140> CURRENT APPLICATION NUMBER: US 09/661,992B
15 <141> CURRENT FILING DATE: 2000-09-14
17 <150> PRIOR APPLICATION NUMBER: AT A157600
18 <151> PRIOR FILING DATE: 1999-09-14
20 <160> NUMBER OF SEQ ID NOS: 112
22 <170> SOFTWARE: PatentIn Ver. 2.1
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 26
26 <212> TYPE: DNA
27 <213> ORGANISM: Artificial Sequence
29 <220> FEATURE:
30 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
31     oligonucleotide MOCG1-2FOR
33 <400> SEQUENCE: 1
34 ctcaattttc ttgtccacct tgggtgc 26
37 <210> SEQ ID NO: 2
38 <211> LENGTH: 26
39 <212> TYPE: DNA
40 <213> ORGANISM: Artificial Sequence
42 <220> FEATURE:
43 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
44     oligonucleotide MOCG3FOR
46 <400> SEQUENCE: 2
47 ctcgattctc ttgatcaact cagtct 26
50 <210> SEQ ID NO: 3
51 <211> LENGTH: 24
52 <212> TYPE: DNA
53 <213> ORGANISM: Artificial Sequence
55 <220> FEATURE:
56 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
57     oligonucleotide MOCMFOR
59 <400> SEQUENCE: 3
60 tggaatgggc acatgcagat ctct 24
63 <210> SEQ ID NO: 4
64 <211> LENGTH: 24

```

RAW SEQUENCE LISTING

DATE: 04/21/2003

PATENT APPLICATION: US/09/661,992B

TIME: 15:32:39

Input Set : A:\-59.app

Output Set: N:\CRF4\04212003\I661992B.raw

```

65 <212> TYPE: DNA
66 <213> ORGANISM: Artificial Sequence
68 <220> FEATURE:
69 <223> OTHER INFORMATION: Description of Artificial Sequence:primer MOCKFOR
71 <400> SEQUENCE: 4
72 ctcattcctg ttgaagctct tgac 24
75 <210> SEQ ID NO: 5
76 <211> LENGTH: 10
77 <212> TYPE: PRT
78 <213> ORGANISM: Artificial Sequence
80 <220> FEATURE:
81 <223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell
82 line 193/AD3 heavy chain CDR3 region
84 <400> SEQUENCE: 5
85 Tyr Gly Asn Ser Pro Lys Gly Phe Ala Tyr
86 1 5 10
89 <210> SEQ ID NO: 6
90 <211> LENGTH: 12
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell
96 line 193/K2 heavy chain CDR3 region
98 <400> SEQUENCE: 6
99 Asp Gly Gly His Gly Tyr Gly Ser Ser Phe Asp Tyr
100 1 5 10
103 <210> SEQ ID NO: 7
104 <211> LENGTH: 13
105 <212> TYPE: PRT
106 <213> ORGANISM: Artificial Sequence
108 <220> FEATURE:
109 <223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell
110 line 193/AB2 (derived from antibody 198/B1) heavy
111 chain CDR3 region, peptide B1
113 <400> SEQUENCE: 7
114 Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Val
115 1 5 10
118 <210> SEQ ID NO: 8
119 <211> LENGTH: 13
120 <212> TYPE: PRT
121 <213> ORGANISM: Artificial Sequence
123 <220> FEATURE:
124 <223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell
125 line 198/A1 heavy chain CDR3 region, peptide A1
127 <400> SEQUENCE: 8
128 Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Val
129 1 5 10
132 <210> SEQ ID NO: 9
W--> 133 <400> SEQUENCE: 9

```

RAW SEQUENCE LISTING

DATE: 04/21/2003

PATENT APPLICATION: US/09/661,992B

TIME: 15:32:39

Input Set : A:\-59.app

Output Set: N:\CRF4\04212003\I661992B.raw

W--> 134 000

```

137 <210> SEQ ID NO: 10
138 <211> LENGTH: 13
139 <212> TYPE: PRT
140 <213> ORGANISM: Artificial Sequence
142 <220> FEATURE:
143 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
144     derived mutated peptide A1/1 scrambled version of
145     A1
147 <400> SEQUENCE: 10
148 Val Tyr Gly Phe Gly Trp Gly Tyr Glu Val Asn Asp Tyr
149   1           5           10
152 <210> SEQ ID NO: 11
153 <211> LENGTH: 18
154 <212> TYPE: PRT
155 <213> ORGANISM: Artificial Sequence
157 <220> FEATURE:
158 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
159     derived mutated peptide A1/2
161 <400> SEQUENCE: 11
162 Glu Glu Glu Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Glu
163   1           5           10           15
165 Glu Glu
168 <210> SEQ ID NO: 12
169 <211> LENGTH: 18
170 <212> TYPE: PRT
171 <213> ORGANISM: Artificial Sequence
173 <220> FEATURE:
174 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
175     derived mutated peptide A1/3
177 <400> SEQUENCE: 12
178 Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
179   1           5           10           15
181 Arg Arg
184 <210> SEQ ID NO: 13
185 <211> LENGTH: 18
186 <212> TYPE: PRT
187 <213> ORGANISM: Artificial Sequence
189 <220> FEATURE:
190 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
191     derived mutated peptide A1/4 scrambled version of
192     A1/2
194 <400> SEQUENCE: 13
195 Glu Tyr Gly Glu Gly Tyr Gly Glu Val Asn Glu Tyr Asp Glu Phe Glu
196   1           5           10           15
198 Trp Glu
201 <210> SEQ ID NO: 14
202 <211> LENGTH: 18
203 <212> TYPE: PRT

```

RAW SEQUENCE LISTING

DATE: 04/21/2003

PATENT APPLICATION: US/09/661,992B

TIME: 15:32:39

Input Set : A:\-59.app

Output Set: N:\CRF4\04212003\I661992B.raw

```

204 <213> ORGANISM: Artificial Sequence
206 <220> FEATURE:
207 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
208     derived mutated peptide A1/5 scrambled version of
209     A1/3
211 <400> SEQUENCE: 14
212 Val Arg Tyr Arg Asn Arg Tyr Arg Trp Gly Tyr Arg Gly Arg Phe Gly
213   1             5             10             15
215 Asp Glu
218 <210> SEQ ID NO: 15
219 <211> LENGTH: 18
220 <212> TYPE: PRT
221 <213> ORGANISM: Artificial Sequence
223 <220> FEATURE:
224 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
225     derived mutated peptide A1/3-scr3 scrambled
226     version of A1/3
228 <400> SEQUENCE: 15
229 Arg Arg Arg Gly Glu Tyr Gly Val Tyr Trp Asn Gly Asp Phe Tyr Arg
230   1             5             10             15
232 Arg Arg
235 <210> SEQ ID NO: 16
W--> 236 <400> SEQUENCE: 16
W--> 237 000
240 <210> SEQ ID NO: 17
W--> 241 <400> SEQUENCE: 17
W--> 242 000
245 <210> SEQ ID NO: 18
W--> 246 <400> SEQUENCE: 18
W--> 247 000
250 <210> SEQ ID NO: 19
251 <211> LENGTH: 18
252 <212> TYPE: PRT
253 <213> ORGANISM: Artificial Sequence
255 <220> FEATURE:
256 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
257     derived mutant peptide A1/3-13 Alanine scan
258     E-1-A-1
260 <400> SEQUENCE: 19
261 Arg Arg Arg Ala Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
262   1             5             10             15
264 Arg Arg
267 <210> SEQ ID NO: 20
268 <211> LENGTH: 18
269 <212> TYPE: PRT
270 <213> ORGANISM: Artificial Sequence
272 <220> FEATURE:
273 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
274     derived mutant peptide A1/3-1 Alanine scan G-2-A-2

```

RAW SEQUENCE LISTING

DATE: 04/21/2003

PATENT APPLICATION: US/09/661,992B

TIME: 15:32:39

Input Set : A:\-59.app

Output Set: N:\CRF4\04212003\I661992B.raw

```

276 <400> SEQUENCE: 20
277 Arg Arg Arg Glu Ala Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
278   1               5               10               15
280 Arg Arg
283 <210> SEQ ID NO: 21
284 <211> LENGTH: 18
285 <212> TYPE: PRT
286 <213> ORGANISM: Artificial Sequence
288 <220> FEATURE:
289 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
290     derived mutant peptide A1/3-2 Alanine scan G-3-A-3
292 <400> SEQUENCE: 21
293 Arg Arg Arg Glu Gly Ala Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
294   1               5               10               15
296 Arg Arg
299 <210> SEQ ID NO: 22
300 <211> LENGTH: 18
301 <212> TYPE: PRT
302 <213> ORGANISM: Artificial Sequence
304 <220> FEATURE:
305 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
306     derived mutant peptide A1/3-3 Alanine scan G-4-A-4
308 <400> SEQUENCE: 22
309 Arg Arg Arg Glu Gly Gly Ala Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
310   1               5               10               15
312 Arg Arg
315 <210> SEQ ID NO: 23
316 <211> LENGTH: 18
317 <212> TYPE: PRT
318 <213> ORGANISM: Artificial Sequence
320 <220> FEATURE:
321 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
322     derived mutant peptide A1/3-4 Alanine scan Y-5-A-5
324 <400> SEQUENCE: 23
325 Arg Arg Arg Glu Gly Gly Gly Ala Tyr Val Asn Trp Tyr Phe Asp Arg
326   1               5               10               15
328 Arg Arg
331 <210> SEQ ID NO: 24
332 <211> LENGTH: 18
333 <212> TYPE: PRT
334 <213> ORGANISM: Artificial Sequence
336 <220> FEATURE:
337 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1
338     derived mutant peptide A1/3-5 Alanine scan Y-6-A-6
340 <400> SEQUENCE: 24
341 Arg Arg Arg Glu Gly Gly Gly Tyr Ala Val Asn Trp Tyr Phe Asp Arg
342   1               5               10               15
344 Arg Arg
347 <210> SEQ ID NO: 25

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/661,992B

DATE: 04/21/2003
TIME: 15:32:40

Input Set : A:\-59.app
Output Set: N:\CRF4\04212003\I661992B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:87; N Pos. 426,675
Seq#:89; N Pos. 228
Seq#:91; N Pos. 228,497,543
Seq#:92; Xaa Pos. 166
Seq#:99; N Pos. 228
Seq#:105; Xaa Pos. 2,3,14,15

VERIFICATION SUMMARY

DATE: 04/21/2003

PATENT APPLICATION: US/09/661,992B

TIME: 15:32:40

Input Set : A:\-59.app

Output Set: N:\CRF4\04212003\I661992B.raw

L:133 M:283 W: Missing Blank Line separator, <400> field identifier
L:134 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (9) SEQUENCE:
L:236 M:283 W: Missing Blank Line separator, <400> field identifier
L:237 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (16) SEQUENCE:
L:241 M:283 W: Missing Blank Line separator, <400> field identifier
L:242 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (17) SEQUENCE:
L:246 M:283 W: Missing Blank Line separator, <400> field identifier
L:247 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (18) SEQUENCE:
L:668 M:283 W: Missing Blank Line separator, <400> field identifier
L:669 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (44) SEQUENCE:
L:1427 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:87 after pos.:420
M:341 Repeated in SeqNo=87
L:1513 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:89 after pos.:180
L:1717 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:91 after pos.:180
M:341 Repeated in SeqNo=91
L:1778 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:92 after pos.:160
L:2175 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:99 after pos.:180
L:2397 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:105 after pos.:0